尤瑞克林联合依达拉奉对大脑中动脉梗死的疗效观察

Effect Observation of Urinary Kallidinogenase Combined With Edaravone on Middle Cerebral Artery Infarction

目的对尤瑞克林联合依达拉奉治疗大脑中动脉梗死的临床疗效进行观察。方法将本院2015年2月—2018年1月治疗的大脑中动脉梗死患者42例,随机平均分成两组,每组21例。在常规治疗基础上,对照组给予丁苯酞氯化钠注射液联合银杏达莫注射液治疗;研究组给予尤瑞克林联合依达拉奉治疗,比较两组的NIHSS评分及改良Rankin量表(mRS)评分,并观察两组的治疗效果。结果研究组总有效率为76.2%,对照组总有效率为42.9%,差异有统计学意义(P<0.05);同时研究组治疗后的NIHSS评分低于对照组,mRS评分高于对照组,差异有统计学意义(P<0.05)。结论大脑中动脉梗死应用尤瑞克林联合依达拉奉治疗,可减少患者的病死率,保证了患者的生存质量,取得良好的疗效。

Objective To observe the clinical effect of urinary kallidinogenase combined with edaravone in the treatment of middle cerebral artery infarction.Methods A total of 42 patients with middle cerebral artery infarction treated in our hospital from February 2015 to January 2018 were randomly divided into two groups,21 patients in each group were treated with butylphthalide sodium chloride injection combined with Ginkgo Damo injection in the control group on the basis of conventional treatment.The study group received uriclinin combined with edaravone.NIHSS score and modified Rankin scale(mRS)score of the two groups were compared,and the treatment effect of the two groups was observed.Results The total effective rate was 76.2%in the study group and 42.9%in the control group,the difference was significant(P<0.05).At the same time,the NIHSS score after treatment in the study group was lower than that in the control group,and the mRS score was higher than that in the control group,the differences were significant(P<0.05).Conclusion The treatment of middle cerebral artery infarction with urinary kallidinogenase combined with edaravone can reduce the mortality of patients,ensure the quality of life of patients,and achieve a good effect.